FAQS

Soybean oil for injection is the core excipient of fat emulsion injections, serving as an energy-supplementing medication that provides essential fatty acids and high-efficiency energy to patients who are unable to receive nutrition orally. The fatty acids produced during its metabolism are among the body’s primary energy sources; under conditions of adequate oxygen supply, they can be completely oxidized to CO₂ and H₂O, releasing substantial amounts of ATP for cellular utilization.

Medium-chain triglycerides (MCTs) are a special type of fat that can bypass the complex digestive process and be rapidly metabolized by the liver into energy for the body. Their metabolic rate is about six times that of long-chain fatty acids, making them less likely to accumulate as body fat. In the medical field, MCTs are primarily used as the core energy source in parenteral nutrition formulations, providing patients who require intravenous nutrition with a readily oxidizable metabolic fuel. They are particularly suitable for patients whose ability to utilize long-chain fatty acids is impaired due to pathological conditions.

Egg yolk lecithin for injection is primarily used as a pharmaceutical excipient, serving as an emulsifier in medicinal products to prepare intravenous nutritional formulations such as fat emulsion injections. It enables uniform mixing of oil-based components with water, forming a stable emulsion that provides energy and essential fatty acids for patients requiring parenteral nutrition.

Soybean oil for injection is primarily used in the manufacture of fat emulsion injections, serving as the core energy source and essential fatty acid supplier for parenteral nutrition (intravenous infusion), and is indicated for patients who require parenteral nutrition to meet their energy needs. In addition, it is a key component in compound formulations such as medium- and long-chain fat emulsion injections and multi-oil fat emulsion injections.

Medium-chain triglycerides are primarily used as raw materials for parenteral nutrition formulations (fat emulsion injections) and enteral nutrition formulations, providing an easily metabolizable energy source for patients requiring intravenous nutrition. In addition, they are also employed in drug-loaded fat emulsion injections (such as propofol medium- and long-chain fat emulsions) and special medical-purpose formula foods, among other products.

Refined egg yolk phosphatidylcholine is primarily used as an emulsifier and membrane-forming material in high-end pharmaceutical formulations such as injectable fat emulsions, liposomes, and microemulsions. Specifically, it serves as a critical excipient in the manufacture of intravenous fat emulsions (e.g., parenteral nutrition preparations) and liposome-encapsulated anticancer drugs, among other pharmaceutical products.

Baiyunshan’s soybean oil for traditional Chinese medicine injections is a high-end, injection-grade pharmaceutical excipient approved by the National Medical Products Administration (Registration No. Y20190001968; Review Status: “A”), with quality that meets multiple standards, including those of the Chinese Pharmacopoeia, the United States Pharmacopeia, and the European Pharmacopoeia. As a leading domestic enterprise in the production of high-end lipid excipients for injectable formulations, this product provided emergency support for vaccine R&D during the COVID-19 pandemic and played a pivotal role in boosting the localization rate of high-end pharmaceutical lipid excipients from 10% to 90%.

Baiyunshan Hanfang Zhonglian Triglycerides is a high-end pharmaceutical excipient that has received marketing approval from the National Medical Products Administration and is primarily used in parenteral nutrition formulations and foods for special medical purposes, among other applications.

Baiyunshan Hanfang Egg Yolk Phosphatidylcholine for Injection is the only domestically produced product in China to have obtained a manufacturing approval from the National Medical Products Administration and achieved industrial-scale production, thereby breaking the long-standing technological monopoly held by German and other foreign companies. This product was jointly reviewed and approved by the Center for Drug Evaluation of the National Medical Products Administration in May 2024.